Objective: To discuss the role of angiotensin-converting enzyme inhibitors in the management of diabetes-related renal disease.
Methods: We review the published data from animal studies and clinical trials and outline the adverse effects that may limit the use of these drugs.
Results: Diabetic nephropathy is the most common cause of end-stage renal disease and dialysis in the United States. With improving measures to optimize blood glucose control and blood pressure, the progression from mild proteinuria to overt renal insufficiency can now be retarded or even arrested. Studies of therapeutic interventions have shown that angiotensin-converting enzyme inhibitors have a superior beneficial effect on nephropathy. Few adverse effects are associated with use of these drugs: a nonproductive cough is the most frequent side effect, and angioedema and agranulocytosis are the most serious (albeit rarely reported) effects.
Conclusion: Angiotensin-converting enzyme inhibitors should be considered as first-line therapy for patients with diabetes who have microalbuminuria or macroalbuminuria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4158/EP.2.3.215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daphnetin may protect from SARS-CoV-2 infection by reducing ACE2.
Sci Rep
December 2024
School of Preclinical Medicine, Wannan Medical College, Wuhu, 241002, China.
To combat the SARS-CoV-2 pandemic, innovative prevention strategies are needed, including reducing ACE2 expression on respiratory cells. This study screened approved drugs in China for their ability to downregulate ACE2. Daphnetin (DAP) was found to significantly reduce ACE2 mRNA and protein levels in PC9 cells.
View Article and Find Full Text PDFOsteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users.
Osteoporos Int
December 2024
Department of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan.
Unlabelled: This study examined the impact of thiazide and RAAS antihypertensive medications vs DHP-RAAS medications on fracture risk. The close alignment of such settings with clinical use, combined with the potential bone benefits of ACEis and ARBs, provides enhanced accuracy in bone health evidence.
Purpose: To determine whether thiazides, combined with either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), offer bone-protective benefits compared with dihydropyridine (DHP) drugs combined with ACEi or ARB.
Antihypertensive Effect of Perla and Esmeralda Barley ( L.) Sprouts in an Induction Model with L-NAME In Vivo.
Metabolites
December 2024
Academic Area of Medicine, Institute of Health Sciences, Autonomous University of the State of Hidalgo, Eliseo Ramírez Ulloa 400, Doctores Pachuca, Pachuca 42090, Hidalgo, Mexico.
Hypertension is one of the leading causes of premature death worldwide. Despite advances in conventional treatments, there remains a significant need for more effective and natural alternatives to control hypertension. In this context, sprouted barley extracts have emerged as a potential therapeutic option.
View Article and Find Full Text PDFNeurological Sequelae of Post-COVID-19 Fatigue: A Narrative Review of Dipeptidyl Peptidase IV-Mediated Cerebrovascular Complications.
Curr Issues Mol Biol
November 2024
Department of Physiology, International Medical School (IMS), Management and Science University, Shah Alam 40150, Selangor, Malaysia.
Coronavirus disease 2019 (COVID-19) has been a global pandemic affecting millions of people's lives, which has led to 'post-COVID-19 fatigue'. Alarmingly, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) not only infects the lungs but also influences the heart and brain. Endothelial cell dysfunction and hypercoagulation, which we know occur with this infection, lead to thrombo-inflammation that can manifest as many myriad cardio-cerebrovascular disorders, such as brain fog, fatigue, cognitive dysfunction, etc.
View Article and Find Full Text PDFImpedimetric Sensor for SARS-CoV-2 Spike Protein Detection: Performance Assessment with an ACE2 Peptide-Mimic/Graphite Interface.
Biosensors (Basel)
December 2024
Escuela de Biotecnología, Facultad de Ciencias, Ingeniería y Tecnología, Universidad Mayor, Camino La Pirámide 5750, Huechuraba, Santiago 8580745, Chile.
The COVID-19 pandemic has prompted the need for the development of new biosensors for SARS-CoV-2 detection. Particularly, systems with qualities such as sensitivity, fast detection, appropriate to large-scale analysis, and applicable in situ, avoiding using specific materials or personnel to undergo the test, are highly desirable. In this regard, developing an electrochemical biosensor based on peptides derived from the angiotensin-converting enzyme receptor 2 (ACE2) is a possible answer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!